CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.
about
Natriuretic Peptides and Cardiometabolic HealthRegulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucomaSoluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucomaIn-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptideIn vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidaGenetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.Endothelial actions of atrial and B-type natriuretic peptidesCenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actionsAssociation of genetic variation with gene expression and protein abundance within the natriuretic peptide pathwayNovel therapeutic targets for the treatment of heart failure.cGMP becomes a drug target.Natriuretic peptides and cGMP signaling control of energy homeostasis.Natriuretic peptides in cardiometabolic regulation and disease.Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.Editor's Choice-Recent therapeutic trials on fluid removal and vasodilation in acute heart failure.MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure.Snake venom toxins: toxicity and medicinal applications.Update on the Management of Acute Decompensated Heart Failure.A New Chimeric Natriuretic Peptide, CNAAC, for the Treatment of Left Ventricular Dysfunction after Myocardial InfarctionPharmacogenomics of the Natriuretic Peptide System in Heart Failure.
P2860
Q26827702-F503AC86-7A86-4D00-ABB0-B0E5C9C1EABDQ26861763-F705CB76-8A21-4275-8B2C-5FC007783304Q27331498-E16DF9BE-2B9A-4259-9EFC-DFD482391A22Q28486215-BA1E89D3-7884-44AB-BA26-E1ADB8D66656Q33804636-28A8D5DB-F20E-4D4D-8553-E62C296C6997Q34304189-17080AFE-4659-4597-BBF3-7195B68B7B10Q36159149-F100076C-6143-4B36-A723-F02A22AEF091Q36860608-D5AA1C30-4568-4674-A2C9-1EF43A13821BQ37227792-2DE18327-58CC-4739-BF59-1EB07DA4AFFAQ37893956-9B069C26-9923-4B18-8DD8-BC88C96B98F7Q37980659-BEFD803C-C24F-41C3-A064-9100924EC02DQ38064374-B6E9DC60-F2BA-4CB8-874C-FAC1F374C594Q38211333-041CDF9B-28E9-481D-9F54-BFFD053F9C40Q38261513-A170CECE-6ED3-40A2-B75A-5B21B8DC20E2Q38270144-07D2E085-BFCF-429A-8EB1-16A9BA0AADF9Q38842507-028CBBFB-A1D4-4B9A-AB5B-53FFC7486439Q38849314-F6A5B267-991F-4221-8B5A-BFAD895D14D4Q39258163-8D1E7FE3-52E4-4985-85B3-288F12FBD362Q41564348-39B4DE43-3A2C-4E25-B5D7-E7152D7F481FQ47596916-4AB8EAE6-26EB-406C-AA31-762194A586C4
P2860
CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD-NP: an innovative designer ...... ptors for cardiorenal disease.
@en
CD-NP: an innovative designer ...... ptors for cardiorenal disease.
@nl
type
label
CD-NP: an innovative designer ...... ptors for cardiorenal disease.
@en
CD-NP: an innovative designer ...... ptors for cardiorenal disease.
@nl
prefLabel
CD-NP: an innovative designer ...... ptors for cardiorenal disease.
@en
CD-NP: an innovative designer ...... ptors for cardiorenal disease.
@nl
P2093
P2860
P1476
CD-NP: an innovative designer ...... ptors for cardiorenal disease.
@en
P2093
John C Burnett
Paul M McKie
S Jeson Sangaralingham
P2860
P2888
P356
10.1007/S11897-010-0016-6
P577
2010-09-01T00:00:00Z